Trial
NCT01006616
Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
COPD
Intervention
Navarixin
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-02